StocksFundsScreenerSectorsWatchlists
TBPH

TBPH - Theravance Biopharma Inc Stock Price, Fair Value and News

9.01USD+0.19 (+2.15%)Market Closed

Market Summary

TBPH
USD9.01+0.19
Market Closed
2.15%

TBPH Alerts

  • Losses in recent quarter

TBPH Stock Price

View Fullscreen

TBPH RSI Chart

TBPH Valuation

Market Cap

434.0M

Price/Earnings (Trailing)

-7.86

Price/Sales (Trailing)

7.56

EV/EBITDA

-8.39

Price/Free Cashflow

-16.07

TBPH Price/Sales (Trailing)

TBPH Profitability

EBT Margin

-85.80%

Return on Equity

-25.91%

Return on Assets

-14.45%

Free Cashflow Yield

-6.22%

TBPH Fundamentals

TBPH Revenue

Revenue (TTM)

57.4M

Rev. Growth (Yr)

19.91%

Rev. Growth (Qtr)

11.93%

TBPH Earnings

Earnings (TTM)

-55.2M

Earnings Growth (Yr)

17.87%

Earnings Growth (Qtr)

4.92%

Breaking Down TBPH Revenue

Last 7 days

3.2%

Last 30 days

1.4%

Last 90 days

-19.2%

Trailing 12 Months

-15.5%

How does TBPH drawdown profile look like?

TBPH Financial Health

Current Ratio

5.39

TBPH Investor Care

Buy Backs (1Y)

23.38%

Diluted EPS (TTM)

-0.97

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202351.3M51.3M54.5M57.4M
202254.3M52.4M52.0M51.3M
202166.3M64.2M59.1M55.3M
202087.9M76.8M82.6M71.9M
201957.4M60.1M59.7M73.4M
201820.6M40.6M49.1M60.4M
201733.3M31.4M16.6M15.4M
201640.1M38.5M46.8M48.6M
201531.1M35.3M39.7M42.1M
20141.1M4.1M10.4M11.7M
2013104.3M78.5M52.7M26.9M
2012000130.1M

Tracking the Latest Insider Buys and Sells of Theravance Biopharma Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Mar 15, 2024
winningham rick e
acquired
23,362
8.64
2,704
chief executive officer
Mar 15, 2024
winningham rick e
gifted
-
-
3,900
chief executive officer
Mar 15, 2024
winningham rick e
gifted
-
-
-10,900
chief executive officer
Feb 22, 2024
farnum rhonda
sold
-10,922
8.71
-1,254
svp, comm & medical affairs
Feb 20, 2024
sawaf aziz
sold (taxes)
-151,961
8.92
-17,036
svp & chief financial officer
Feb 20, 2024
graham richard a
sold (taxes)
-172,102
8.92
-19,294
svp, research & development
Feb 20, 2024
farnum rhonda
sold (taxes)
-162,513
8.92
-18,219
svp, comm & medical affairs
Feb 20, 2024
miller aine
sold (taxes)
-105,095
8.92
-11,782
svp, dev & head of ire office
Feb 20, 2024
grimaud brett a.
sold (taxes)
-156,947
8.92
-17,595
svp, gen counsel and secretary
Feb 20, 2024
winningham rick e
sold (taxes)
-331,788
8.92
-37,196
chief executive officer

1–10 of 50

Which funds bought or sold TBPH recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Mar 22, 2024
PNC FINANCIAL SERVICES GROUP, INC.
reduced
-2.08
343
1,585
-%
Mar 11, 2024
VANGUARD GROUP INC
reduced
-9.12
6,085,900
39,219,300
-%
Mar 05, 2024
GERBER, LLC
new
-
112,400
112,400
0.10%
Mar 01, 2024
GOLDMAN SACHS GROUP INC
added
112
4,107,580
6,435,820
-%
Feb 28, 2024
AMERICAN INTERNATIONAL GROUP, INC.
reduced
-8.99
45,008
287,856
-%
Feb 20, 2024
Pacific Center for Financial Services
unchanged
-
149
641
-%
Feb 16, 2024
PRICE T ROWE ASSOCIATES INC /MD/
reduced
-4.33
102,000
517,000
-%
Feb 16, 2024
Madison Avenue Partners, LP
unchanged
-
18,301,900
78,817,400
11.13%
Feb 16, 2024
GSA CAPITAL PARTNERS LLP
reduced
-76.36
-1,947,000
866,000
0.07%
Feb 15, 2024
Legal & General Group Plc
reduced
-9.00
88,490
566,429
-%

1–10 of 48

Are Funds Buying or Selling TBPH?

Are funds buying TBPH calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own TBPH
No. of Funds

Unveiling Theravance Biopharma Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Mar 05, 2024
weiss asset management lp
15.5%
7,457,060
SC 13D/A
Feb 14, 2024
irenic capital management lp
5.5%
2,760,948
SC 13G
Feb 13, 2024
vanguard group inc
7.01%
3,489,262
SC 13G/A
Feb 08, 2024
blackrock inc.
9.2%
4,584,596
SC 13G/A
Aug 14, 2023
weiss asset management lp
14.%
7,457,060
SC 13D/A
Jul 10, 2023
baupost group llc/ma
12.84%
7,419,226
SC 13G/A
Apr 12, 2023
weiss asset management lp
11.%
7,457,060
SC 13D
Feb 14, 2023
orbimed advisors llc
0%
0
SC 13G/A
Feb 14, 2023
madison avenue partners, lp
10.4%
7,012,226
SC 13G/A
Feb 13, 2023
baupost group llc/ma
16.95%
11,419,226
SC 13G/A

Recent SEC filings of Theravance Biopharma Inc

View All Filings
Date Filed Form Type Document
Mar 19, 2024
4
Insider Trading
Mar 05, 2024
SC 13D/A
13D - Major Acquisition
Mar 01, 2024
10-K
Annual Report
Feb 28, 2024
8-K
Current Report
Feb 26, 2024
8-K
Current Report
Feb 22, 2024
4
Insider Trading
Feb 22, 2024
4
Insider Trading
Feb 22, 2024
4
Insider Trading
Feb 22, 2024
4
Insider Trading
Feb 22, 2024
4
Insider Trading

Peers (Alternatives to Theravance Biopharma Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
42.3B
6.8B
19.31% -24.90%
-8.96
6.17
-64.45% -156.37%
22.4B
152.6K
-0.77% 465779.94%
-2.4K
146.8K
- -9.98%
19.4B
1.8B
-0.33% -18.28%
-44.17
10.64
76.23% 61.08%
16.7B
2.4B
-4.10% -7.32%
99.73
6.91
15.42% 18.43%
12.8B
3.7B
-1.69% -18.94%
21.46
3.47
8.87% 75.42%
MID-CAP
7.1B
396.6M
-19.47% -8.81%
-13.34
17.78
425.83% 18.94%
5.4B
-
-20.51% 118.30%
-8.31
60.35
54.84% -34.79%
3.8B
270.6M
-13.09% 29.37%
-15.68
13.86
440.80% -27.84%
3.6B
240.7M
-7.70% 7.49%
-11.98
14.77
-1.03% -92.09%
3.0B
726.4M
-28.51% -9.28%
-48.93
4.13
40.45% 71.62%
SMALL-CAP
1.9B
398.2M
12.36% 9.77%
26.85
4.82
85.90% -14.05%
678.8M
983.7M
12.98% -18.87%
-1.25
0.69
-50.36% 17.16%
373.2M
881.7K
51.26% 463.55%
-8.37
466.16
-77.61% -5.33%
304.5M
4.9M
46.53% -11.16%
-2.25
62.57
-54.97% 51.72%
11.8M
2.1M
-13.49% -43.81%
-0.43
2.14
-13.45% 66.37%

Theravance Biopharma Inc News

Latest updates
Defense World • 3 hours ago
Yahoo Finance • 28 Feb 2024 • 08:00 am
InvestorsObserver • 28 Feb 2024 • 08:00 am
Simply Wall St • 28 Feb 2024 • 08:00 am
Zacks Investment Research • 26 Feb 2024 • 08:00 am

Theravance Biopharma Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Revenue11.9%17,565,00015,693,00013,749,00010,417,00014,649,00012,451,00011,750,50011,050,00013,196,00014,946,00013,194,00012,914,00014,257,00018,730,00018,257,00015,008,00019,862,00029,499,00012,427,00026,150,0005,338,000
Operating Expenses-2.6%23,805,00024,453,00029,872,00035,329,00032,081,00026,653,000-34,151,00050,419,00071,113,00066,809,00077,024,00098,149,00095,220,00094,872,00087,184,00092,338,000100,071,00077,628,00068,626,00079,004,000
  S&GA Expenses-4.0%15,492,00016,142,00019,278,00019,183,00016,732,00016,277,000-16,222,00017,842,00021,516,00021,299,00025,931,00030,550,00029,925,00027,501,00024,780,00026,325,00033,046,00025,622,00022,227,00025,186,000
  R&D Expenses0.0%8,313,0008,311,0009,425,00014,572,00015,348,0009,867,000-14,924,00023,253,00031,226,00043,739,00051,093,00067,599,00065,165,00067,371,00062,404,00066,013,00067,025,00052,006,00046,399,00053,818,000
EBITDA Margin20.8%-0.82-1.03-1.18-1.31-1.62-2.79-3.53-3.51-3.76-4.23-4.52-4.29-4.32--------
Interest Expenses2.3%623,000609,000568,000550,000550,0001,545,000-2,137,0002,137,000-7,468,5002,136,00011,612,00011,873,000-24,358,00011,573,00011,391,0009,941,0008,035,0008,068,0007,901,0007,858,000
Income Taxes155.2%3,488,0001,367,0001,500,000-395,000-3,000-507,000--5,000524,0001,756,000-7,000-220,000227,000-8,799,00093,00039,000147,00049,000-5,552,000201,00080,000
Earnings Before Taxes33.9%-5,016,000-7,583,000-14,187,000-22,483,000-14,259,000-16,023,000--22,798,000-39,735,000-67,597,000-55,917,000-52,625,000-79,452,000-84,039,000-73,550,000-62,848,000-82,906,000-65,557,000-63,983,000-39,637,000-72,500,000
EBT Margin20.1%-0.86-1.07-1.31-1.47-1.81-2.83-3.58-3.55-3.98-4.62-4.60-4.51-4.53--------
Net Income4.9%-8,510,000-8,950,000-15,645,000-22,088,000-10,362,000916,631,000--8,191,000-25,946,000-32,034,000-35,308,000-52,405,000-79,679,000-58,434,000-73,643,000-62,887,000-83,053,000-65,606,000-58,431,000-39,838,000-72,580,000
Net Income Margin8.2%-0.96-1.0516.9417.0016.99-1.96-1.95-1.94-2.69-3.61-3.82-4.12-4.15--------
Free Cashflow65.6%-854,000-2,486,000-13,074,000-11,859,000-124,693,000-22,775,000-15,368,000-15,368,000-26,707,000-43,072,000-46,084,000-50,751,000-70,503,000--------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets-7.6%38241444753960776372.00361355375403429375469512564605409445492531
  Current Assets-17.4%134162192261353512-15520525029733329339345149853437.00356426467
    Cash Equivalents-43.7%40.0072.0010618829841929.0087.0094.0091.0012120511481.0093.0010533359.00102178223
  Net PPE-2.4%9.009.0010.0012.0012.0012.00-13.0013.0014.0016.0017.0017.0016.0015.0014.0014.0013.0012.0013.0013.00
  Current Liabilities-2.4%25.0025.0025.0026.0029.00142-33.0044.0059.0066.0067.0086.0012410410798.003.00109110114
Shareholder's Equity-13.5%213246280371442481----338-----------
  Retained Earnings-0.9%-909-900-891-876-853-843--1,760-1,751-1,726-1,694-1,658-1,606-1,526-1,468-1,394-1,331-1,248-1,182-1,124-1,084
  Additional Paid-In Capital-2.2%1,1221,1471,1721,2471,2961,324-1,4101,4011,3871,3701,3581,2331,2231,2071,1921,1731,0251,000987972
Shares Outstanding-5.4%48.0051.0054.0061.0065.0076.0076.0076.0075.0074.0068.0066.0064.00--------
Float--------677---882---1,280---893-
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Cashflow From Operations65.6%-0.85-2.49-12.44-11.22-124-22.14-14.73-26.07-42.43-45.45-50.11-69.86-64.92-77.03-53.35-55.10-64.35-44.62-48.03-81.19-52.18
  Share Based Compensation-7.0%6.006.006.007.007.009.0010.0015.0017.0014.0015.0016.0016.0016.0017.0015.0024.0013.0011.0012.0012.00
Cashflow From Investing-3123.8%-0.68-0.0211.00-43.0539.001,0758.0032.0011.00-35.7936.0011452.0067.00-17668.0014.00-23.66-1.30-72.1699.00
Cashflow From Financing2.5%-30.61-31.40-80.68-56.24-35.47-7220.00-1.450.00-2.29105-11.291.00-0.962.00261-1.54-0.134.00-1.43230
  Buy Backs-2.0%30.0031.0081.0055.00-94.00---------------

TBPH Income Statement

2023-12-31
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Revenue:  
Total revenue$ 57,424,000$ 51,346,000
Expenses:  
Research and development[1]40,621,00063,392,000
Selling, general and administrative[1]70,095,00067,073,000
Restructuring and related expenses[1]2,743,00012,838,000
Total expenses113,459,000143,303,000
Loss from operations(56,035,000)(91,957,000)
Interest expense[2](2,350,000)(6,369,000)
Loss on extinguishment of debt (3,034,000)
Interest income and other income (expense), net9,116,0008,545,000
Loss from continuing operations before income taxes(49,269,000)(92,815,000)
Provision for income tax expense(5,924,000)(9,000)
Net loss from continuing operations(55,193,000)(92,824,000)
Income from discontinued operations before income taxes 1,143,930,000
Provision for income tax expense (178,974,000)
Net income from discontinued operations 964,956,000
Net Income (Loss)$ (55,193,000)$ 872,132,000
Net income (loss) per share:  
Continuing operations - basic (in dollars per share)$ (1.00)$ (1.26)
Continuing operations - diluted (in dollars per share)(1.00)(1.26)
Discontinued operations - basic (in dollars per share) 13.11
Discontinued operations - diluted (in dollars per share) 13.11
Net income (loss) - basic (in dollars per share)(1.00)11.85
Net income (loss) - diluted (in dollars per share)$ (1.00)$ 11.85
Shares used to compute net income (loss) per share - basic55,30373,591
Shares used to compute net income (loss) per share - diluted55,30373,591
Viatris collaboration agreement  
Revenue:  
Total revenue$ 57,201,000$ 48,624,000
Viatris royalties (Non-US)  
Revenue:  
Total revenue7,00030,000
Collaboration revenue  
Revenue:  
Total revenue$ 216,000192,000
Licensing revenue  
Revenue:  
Total revenue $ 2,500,000
[1]Amounts include share-based compensation expense as follows:
[2]Interest expense for the year ended December 31, 2023 was comprised of non-cash interest expense only.

TBPH Balance Sheet

2023-12-31
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 39,545$ 298,172
Short-term marketable securities62,88129,312
Receivables from collaborative arrangements17,47416,785
Prepaid clinical and development services2,0381,513
Other prepaid and current assets11,6037,682
Total current assets133,541353,464
Property and equipment, net9,06811,875
Operating lease assets36,28740,126
Future contingent milestone and royalty assets194,200194,200
Restricted cash836836
Other assets8,0676,899
Total assets381,999607,400
Current liabilities:  
Accounts payable1,5241,554
Accrued personnel-related expenses6,44310,314
Accrued clinical and development expenses2,2464,932
Accrued general and administrative expenses2,9004,020
Operating lease liabilities3,9236,753
Tenant improvement payable to subleasee6,490 
Other accrued liabilities1,2411,142
Total current liabilities24,76728,715
Long-term operating lease liabilities45,23645,407
Future royalty payment contingency27,78825,438
Long-term deferred revenue 192
Unrecognized tax benefits65,29464,191
Other long-term liabilities5,9191,657
Commitments and contingencies
Shareholders' Equity  
Preferred shares, $0.00001 par value: 230 shares authorized, no shares issued or outstanding
Ordinary shares, $0.00001 par value: 200,000 shares authorized; 48,091 and 65,227 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively 1
Additional paid-in capital1,122,1641,295,725
Accumulated other comprehensive loss(65)(15)
Accumulated deficit(909,104)(853,911)
Total shareholders' equity212,995441,800
Total liabilities and shareholders' equity$ 381,999$ 607,400
TBPH
Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States and Europe. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD). The company's product includes Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; and TRELEGY for the treatment of COPD and asthma. It has licensing and collaboration agreements with Pfizer Inc. for its preclinical skin-selective pan-JAK inhibitor program, as well as Viatris Inc. Theravance Biopharma, Inc. was incorporated in 2013 and is based in George Town, the Cayman Islands.
 CEO
 WEBSITEwww.theravance.com
 EMPLOYEES111

Theravance Biopharma Inc Frequently Asked Questions


What is the ticker symbol for Theravance Biopharma Inc? What does TBPH stand for in stocks?

TBPH is the stock ticker symbol of Theravance Biopharma Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Theravance Biopharma Inc (TBPH)?

As of Wed Mar 27 2024, market cap of Theravance Biopharma Inc is 433.96 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of TBPH stock?

You can check TBPH's fair value in chart for subscribers.

What is the fair value of TBPH stock?

You can check TBPH's fair value in chart for subscribers. The fair value of Theravance Biopharma Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Theravance Biopharma Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for TBPH so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Theravance Biopharma Inc a good stock to buy?

The fair value guage provides a quick view whether TBPH is over valued or under valued. Whether Theravance Biopharma Inc is cheap or expensive depends on the assumptions which impact Theravance Biopharma Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for TBPH.

What is Theravance Biopharma Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Mar 27 2024, TBPH's PE ratio (Price to Earnings) is -7.86 and Price to Sales (PS) ratio is 7.56. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. TBPH PE ratio will change depending on the future growth rate expectations of investors.